Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03530254 · ClinicalTrials.gov registry record · NA

Clinical Study of PGT-A Versus PGT-A+ERA

A NA study, sponsored by Igenomix.

Terminated
Registry status
NA
Development phase
368
Enrollment target

NCT03530254 is a NA study that was terminated before completion, run by Igenomix. The registered enrollment target is 368 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03530254, a NA study, was terminated before completion, sponsored by Igenomix.

TERMINATED
Registry status
NA
Development phase
368 participants
Enrollment target

Study Summary

Patients who have shown previous implantation failures, despite transferring good quality and chromosomally normal embryos (diagnosed by PGT-A), could have a displaced Window of Implantation (WOI) and consequently, alterations in their endometrial receptivity. The correction of this displacement can improve the results of the Assisted Reproduction Treatments (ART). The ERA test (Endometrial Receptivity Analysis) evaluates the transcriptomic endometrial profile to determine if the patient's uterus is receptive when the embryo is transferred during an In Vitro Fertilization (IVF) process, and identifies the personalized WOI of the patient. This process is called Personalized Embryo Transfer (pET). The Preimplantation Genetic Test of Aneuploidies or PGT-A (Preimplantation Genetic Testing for Aneuploidy), is currently carried out using Next Generation Sequencing (NGS) and serves to identify chromosomally normal embryos prior to their transfer in an IVF treatment. Aneuploidies are rarely compatible with life or can cause congenital diseases. So, the identification of chromosomally normal embryos, improves the success of reproduction in cases in which infertility is caused by such aneuploidies. Therefore, the aim of this study is to determine, in a randomized and prospective way, the clinical benefit of adding the ERA test to the embryonic aneuploidies test for patients with a PGT-A indication.

Interventions

  • DIAGNOSTIC_TEST PGT-A
  • DIAGNOSTIC_TEST ERA Test

Trial Details

FieldValue
Enrollment Target 368 participants
Start Date 2018-05-28
Est. Completion 2022-02-22
Phase NA

Sponsor

Igenomix

4 total trials

What the Registry Record Tells You About NCT03530254

The ClinicalTrials.gov registry entry for NCT03530254 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 368 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Igenomix, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which PGT-A is the first listed.

NCT03530254 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03530254 about?

NCT03530254 is a clinical study titled "Clinical Study of PGT-A Versus PGT-A+ERA". Patients who have shown previous implantation failures, despite transferring good quality and chromosomally normal embryos (diagnosed by PGT-A), could have a displaced Window of Implantation (WOI) and consequently, alterations in their endometrial receptivity. The correction of this displacement can...

What is the current status of trial NCT03530254?

This trial is currently terminated. It is a NA study. The enrollment target is 368 participants. The study started on 2018-05-28. Estimated completion is 2022-02-22.

What interventions are being tested in trial NCT03530254?

The interventions under investigation include: PGT-A (DIAGNOSTIC_TEST), ERA Test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03530254?

This trial is sponsored by Igenomix, which has 4 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.